ArticleCancer immunology, immunotherapy : CII2026
Non-thyroidal illness syndrome predicts poor prognosis in hepatocellular carcinoma patients treated with atezolizumab and bevacizumab.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAtezolizumab plus bevacizumab (Ate/Bev) is the first-line systemic therapy for unresectable hepatocellular carcinoma (HCC). However, the prognostic impact of immune-related thyroid adverse events (irTAEs), particularly non-thyroidal illness syndrome (NTIS), remains unclear.
methodsWe retrospectively analyzed 70 patients with unresectable HCC treated with Ate/Bev. Thyroid function was monitored at baseline and during the treatment. IrTAEs were classified as NTIS (low T3 and/or free T4 with normal or low TSH levels) or thyroid adverse events (hypothyroidism or thyrotoxicosis). Clinical outcomes, including progression-free survival (PFS) and overall survival (OS), were assessed using Kaplan-Meier and Cox regression analysis. Subgroup analyses were performed to examine the associations between liver function, nutritional status, and HCC etiology.
resultsAmong 70 patients (median age, 64 years; 80% male), 24 (34.3%) developed irTAEs: 11 had NTIS and 13 had thyroid AEs. NTIS was independently associated with worse OS (adjusted hazard ratio [HR], 2.51; P = 0.041) and shorter median OS (5.4 months). In contrast, thyroid AEs were associated with a favorable trend in PFS (adjusted HR, 0.37; P = 0.073) and a higher objective response rate (53.8% vs. 9.1%; P = 0.006). NTIS was correlated with deterioration in albumin level, body mass index, and ALBI grade. Viral HCC was associated with fewer thyroid AEs, while alcohol-related HCC trended toward NTIS.
conclusionsThyroid dysfunction during Ate/Bev therapy is prognostically significant. NTIS reflects systemic deterioration and portends poor survival, whereas thyroid AEs may suggest favorable immune activation. Routine monitoring of thyroid function may aid in risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.